From GlobeNewswire: 2025-04-27 15:00:00

Y-mAbs Therapeutics presented preclinical and translational pharmacokinetics data of CD38-SADA at the AACR Annual Meeting. The study tracked plasma concentrations of CD38-SADA in animal models over time and doses, providing insights for first-in-human pretargeted radioimmunotherapy. The CD38-SADA protein showed significantly reduced levels before delivering the radioactive payload, impacting tumor-to-normal tissue absorbed dose ratios. Researchers at MSK developed the SADA technology exclusively licensed to Y-mAbs for PRIT. CD38-SADA is a bispecific fusion protein showing anti-tumor efficacy in preclinical studies and currently being investigated in adults with relapsed NHL. The Company also provided forward-looking statements about its business model and financial outlook for 2024 and beyond, highlighting potential risks and challenges.



Read more at GlobeNewswire: Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA